Home
June 2008 July 2008 August 2008
Su Mo Tu We Th Fr Sa
Week 27 1 2 3 4 5
Week 28 6 7 8 9 10 11 12
Week 29 13 14 15 16 17 18 19
Week 30 20 21 22 23 24 25 26
Week 31 27 28 29 30 31

Sildenafil Has Beneficial Vascular Effects in Cardiac Transplant Recipients Show Comments PDF Print E-mail
Friday, 24 October 2003
NEW YORK (Reuters Health) - Sildenafil (Viagra), the popular erectile dysfunction drug, improves blood pressure and has other beneficial vascular effects in cardiac transplant recipients with hypertension, new research shows.

NEW YORK (Reuters Health) - Sildenafil (Viagra), the popular erectile dysfunction drug, improves blood pressure and has other beneficial vascular effects in cardiac transplant recipients with hypertension, new research shows.

Hypertension can be difficult to control in transplant recipients and often multiple agents are required. Moreover, the cardiac denervation present in these recipients means that circulatory adjustments are often limited to changes in arterial blood pressure. So, any drug with direct vascular effects could potentially be useful in such patients.

In a study reported in the October issue of the American Journal of Hypertension, Dr. Richard S. Schofield, from the University of Florida College of Medicine n Gainesville, and colleagues looked at the vascular effects of sildenafil in 15 hypertensive male cardiac transplant recipients. Several central and peripheral hemodynamic parameters were measured before and after the patients were given 50 mg of sildenafil.

Sildenafil treatment produced a significant improvement in brachial and aortic systolic blood pressure, pulse pressure, left ventricular tension time index, aortic augmentation index, travel time of the reflected aortic pressure wave, and brachial artery reactivity (p < 0.01 for all).

Although the patients continued their usual antihypertensive drugs, none became hypotensive when sildenafil was added, the researchers note.

"The favorable effects of sildenafil on several measures of vascular function indicate that this novel compound may warrant further investigation for use as a chronic vasodilator in cardiac transplant recipients with chronic post-transplant hypertension," they add.

Am J Hypertens 2003;16:874-877.


Copyright © 2003 Reuters Limited. All rights reserved. Republication or redistribution of Reuters Limited content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters Limited. Reuters Limited shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 0
PoorBest


 
< Prev   Next >